As of May 23, 2025, Vistagen Therapeutics Inc (VTGN) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Vistagen Therapeutics Inc's Forward P/E to Peers
To better understand Vistagen Therapeutics Inc's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Vistagen Therapeutics Inc (VTGN) | - |
| Vertex Pharmaceuticals Inc (VRTX) | 23.76 |
| Regeneron Pharmaceuticals Inc (REGN) | 16.41 |
| Abbvie Inc (ABBV) | 14.47 |
| Gilead Sciences Inc (GILD) | 13.28 |
| Amgen Inc (AMGN) | 12.93 |
Compared to its competitors, Vistagen Therapeutics Inc's Forward P/E is difficult to compare due to insufficient data.